NASDAQ:ADVM
ADVM Stock News
$8.93
-0.240 (-2.62%)
At Close: May 14, 2024
-- Results featured in a presentation today at the Retina Society's 54 th Annual Scientific Meeting -- -- Robust aflibercept protein expression sustained through 2 years --
Adverum to Present Data from ADVM-022 Clinical Trials at Upcoming Medical Conferences
09:00am, Monday, 27'th Sep 2021
REDWOOD CITY, Calif., Sept. 27, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases,
Adverum Appoints Global Regulatory Leader Jim Wang, Ph.D., as Senior Vice President, Head of Regulatory Affairs
09:00am, Monday, 23'rd Aug 2021
REDWOOD CITY, Calif., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, t
Adverum Announces Changes to Management Team
04:05pm, Thursday, 24'th Jun 2021
-- Christopher J. DeRespino appointed acting CFO -- -- Peter Soparkar appointed COO --
A Trio of Net Current Asset Value Stock Picks
12:07pm, Wednesday, 09'th Jun 2021
There are some investors who invest in U.S.-listed stocks that are trading below their liquidation values because they believe they can gain from these allocations after the market has reappraised the
Why Adverum Biotechnologies Stock Sank in May
10:00am, Monday, 07'th Jun 2021
The uncertainty over the biotech's lead clinical asset weighed on its shares last month.
Are Options Traders Betting on a Big Move in Adverum (ADVM) Stock?
09:46am, Tuesday, 18'th May 2021
Investors need to pay close attention to Adverum (ADVM) stock based on the movements in the options market lately.
Adverum Biotechnologies (ADVM) is Oversold: Can It Recover?
08:16am, Monday, 17'th May 2021
Adverum Biotechnologies (ADVM) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
The Sonic Fund II, L.P. Comments on Preliminary Voting Results of Adverum Annual Meeting
03:17pm, Wednesday, 12'th May 2021
HONOLULU--(BUSINESS WIRE)--The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Com
Adverum Stockholders Re-Elect All Adverum Director Nominees at 2021 Annual Meeting
01:05pm, Wednesday, 12'th May 2021
REDWOOD CITY, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, to
The Sonic Fund II, L.P. Issues Statement to Adverum Stockholders
03:15pm, Tuesday, 11'th May 2021
HONOLULU--(BUSINESS WIRE)--The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - ADVM
05:00am, Tuesday, 11'th May 2021
NEW YORK, May 11, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Adverum Biotechnologies, Inc. ("Adverum" or the "Company") (NASDAQ: ADVM). Such investors a
HONOLULU--(BUSINESS WIRE)--The Sonic Fund II, L.P. (“Sonic”), which beneficially owns approximately 6.8% of the outstanding common stock of Adverum Biotechnologies, Inc. (NASDAQ: ADVM) (the “Com
Adverum Biotechnologies (ADVM) Reports Q1 Loss, Tops Revenue Estimates
06:01pm, Thursday, 06'th May 2021
Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of 23.68% and 1530.44%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the sto
2 Falling Knives to Catch
02:14pm, Thursday, 06'th May 2021
Akebia Therapeutics Inc ( AKBA , Financial), Adverum Biotechnologies Inc ( ADVM , Financial) have performed so poorly over the prior 52 weeks through May 5, with the share prices losing more than 59%,
